Psychotropic medicines on the 23rd WHO Essential Medicine List

The new mental health section of the WHO EML is presented in Table 1, which reports the medicines with indications for mental disorders, the year of first introduction on the WHO EML and its evolution over the years since 1977. The updated WHO EML includes twenty-three essential medicines for mental disorders, ten of which are antipsychotics (six second-generation and four first-generation antipsychotics), eight are antidepressants (six selective-serotonin reuptake inhibitors and two tricyclic antidepressants), three are mood stabilizers and two are benzodiazepines (Table 1). Essential psychotropic medicines are listed for five priority mental disorders, namely psychotic, depressive, bipolar, anxiety and obsessive-compulsive disorders.

Table 1. Medicines with an indication for mental disorders on the 23rd WHO Essential Medicine List

The revision determined an increase in the overall number of medicines considered essential for mental disorders, with a balance between old and new medicines: some widely available and affordable medicines are still on the list after more than 45 years (e.g., haloperidol, chlorpromazine, fluphenazine long-acting, amitriptyline, lithium, carbamazepine and diazepam), together with others recently added to represent current best evidence-based choices. Notably, for antipsychotics, this balance refers also to short- and long-acting intramuscular formulations, with the presence of short-acting olanzapine and long-acting paliperidone (1-month formulation) and risperidone (Table 1) (Ostuzzi et al., Reference Ostuzzi, Gastaldon, Papola and Barbui2022).

In the updated WHO EML, some psychotropic medicines are considered essential for different conditions. For example, aripiprazole, olanzapine, paliperidone and quetiapine are listed as essential medicines for both psychotic and bipolar disorders, and selective serotonin uptake inhibitors are listed as essential for depressive, anxiety and obsessive-compulsive disorders. This approach allowed us to keep a balance between the need to list a relatively low number of medicines, in agreement with the concept of being essential, and the pressing need to align the WHO EML with the current best international and national standards on the pharmacological treatment of mental disorders. The new WHO EML is this way reinforced in its role of being a reference model list for countries that want to implement evidence-based choices and not only for countries that want to select the most affordable medicines.

In the new WHO EML, all psychotropic medicines with a ‘square box’ have a restricted list of specific alternative medicines that are considered therapeutic equivalents, as opposed to previous versions of the list which included several ‘unrestricted’ square boxes, implying that any medicines of the same pharmacological class could be considered as effective therapeutic alternatives (Cappello et al., Reference Cappello, Moja, Figueras and Magrini2020). This change increases the focus of the list, as now each therapeutic alternative is named and gives more value to the background evidence for each medicine rather than making general assumptions about the therapeutic equivalence of medicines in the same pharmacological class.

In line with WHO recommendations of considering pharmacological treatment for mental disorders only in adolescents from 13 years of age (World Health Organization, 2016), haloperidol, chlorpromazine and fluoxetine were removed from the children WHO EML. Notably, this implies that there are no more essential psychotropic medicines for children up to 12 years of age.

The WHO Expert Committee did not accept the recommendation of adding phenelzine for treatment-resistant depression and paliperidone 3-month long-acting intramuscular injections. For phenelzine, it was argued that the evidence of efficacy in treatment-resistant depression is almost absent, and that there are safety issues requiring specialist expert knowledge. Additionally, the use of phenelzine requires adherence to certain dietary requirements, and coadministration of some medicines should be avoided. For these reasons, this medicine is usually prescribed in specialized settings. For paliperidone 3-month long-acting intramuscular injections, the WHO Committee noted that it is not recommended to initiate treatment with the 3-month formulation, rather it is used in patients who demonstrate benefit and tolerance to the 1-month formulation over at least four months. In addition, there is no clear evidence that this formulation is cost-effective compared to paliperidone 1-month long-acting injections, which is already on the list, and available as a generic.

Availability potential of essential psychotropic medicines

At the country level, using the WHO EML as a reference guide for psychotropic medicine selection should contemplate the differential availability potential of the medicines on the list. Availability pertains to the obtainability of medicines in the public and private sectors (Bigdeli et al., Reference Bigdeli, Jacobs, Tomson, Laing, Ghaffar, Dujardin and Van Damme2013). At the country level, availability is determined by processes for medicine regulation and functional supply systems, including procurement and distribution chains. Notably, some medicine characteristics may facilitate or hamper availability, depending on each country's organization of healthcare. Borrowing the taxonomy of elements that make psychosocial interventions scalable in LMICs, that is being transdiagnostic, task-shifting and low-resource intensity (World Health Organization, 2017b), the country level availability potential of the medicines included in the revised mental health section of the WHO EML may be outlined, as suggested in Table 2.

Table 2. Availability potential of medicines for mental disorders included on the 23rd WHO Essential Medicine List

Trans-diagnostic: Yes = medicines can be used to target specific symptoms occurring in different mental disorders; No = medicines can be used for a specific diagnosis or indication or label; Partially = medicines can be used in two or more mental disorders.

Task-shifting: Yes = medicines can be used by non-specialist healthcare providers who are trained to prescribe pharmacological treatments; No = medicines can be used by non-specialist healthcare providers who are trained to prescribe pharmacological treatments only in consultation with a specialist or under the supervision of a specialist.

IP = initial prescribing; CP = continued prescribing only.

Monitoring: High-intensity = regular clinical, laboratory and ECG monitoring required; medium-intensity = regular clinical, laboratory and ECG monitoring suggested; low-intensity = regular clinical, laboratory and ECG monitoring as needed.

Buyer price: Price available to organizations conducting the tender or procurement, e.g. South Africa Department of Health, Peru Department of Health, Organization for Eastern Caribbean Procurement Services, etc.; supplier price: price available to organizations who maintain a warehouse and supply items directly to customers, e.g. UNICEF supply division, United Nation population fund, Affordable medicines for Africa, etc. Source: MSH International medical products price guide: https://mshpriceguide.org/en/home/ (year 2015).

First, some essential psychotropic medicines can be considered transdiagnostic, implying that they can be used to target specific symptoms across disorders rather than specific diagnostic entities, such as, for example, benzodiazepines and first-generation antipsychotics. By contrast, other medicines can be used for a specific diagnosis or indication or label, such as clozapine, lithium or carbamazepine. Some other medicines may be considered partially transdiagnostic, such as second-generation antipsychotics or antidepressants, as they can be used for different mental disorders (Table 2). At the country level, the medicine selection process should carefully consider these differences, as they would imply, for the selected medicines, specific regulatory decisions which, in turn, may strongly affect availability, such as, for example, labelling some medicines for use in individuals with specific diagnoses versus specific symptoms (Barbui et al., Reference Barbui, Dua, Kolappa, Saraceno and Saxena2017).

Second, almost all essential psychotropic medicines on the WHO EML might be subject to a task-shifting delivering modality; that is, they might be prescribed by non-specialist healthcare providers who are trained to prescribe pharmacological treatments. This position is already supported by several organizations, including the WHO, which advocates the prescription of psychotropic medicines by non-specialists, except clozapine and lithium (World Health Organization, 2016). These two medicines are generally recommended to be used by non-specialist healthcare providers only in consultation with a specialist or under the supervision of a specialist (Table 2). Notably, clozapine and lithium would also need a medical doctor to issue initial and continued prescriptions. Depending on country regulations, the same may not apply to other essential psychotropic medicines, which may be prescribed by trained non-medical staff, for example antidepressants and benzodiazepines (Maier, Reference Maier2019). For some other medicines, initial prescribing may be up to a medical doctor, with continued prescribing up to non-medical staff, say for example antipsychotics or mood stabilizers (Table 2). At the country level, these prescribing considerations should inform the selection process, as they imply, for the selected medicines, regulatory decisions on which medicines may be prescribed by doctors only or also by other professionals, including initial and subsequent prescriptions, and a decision on the level of the healthcare system where each essential psychotropic medicine should be available.

Third, some essential psychotropic medicines require specific and high-intensity monitoring, for example clozapine and lithium, and this may decrease their availability potential, while other medicines are generally prescribed alongside regular clinical, laboratory and ECG monitoring, for example antipsychotics and mood stabilizers, which may also be an obstacle to availability in some settings (Table 2). Among essential psychotropic medicines, antidepressants and benzodiazepines usually need clinical, laboratory and ECG monitoring on a less intense basis (Table 2). As for the previous considerations, at the country level, the selection process should take these monitoring requirements into due consideration, as they imply, for the selected medicines, specific regulatory decisions on monitoring requirements affecting availability to the end-users.

Fourth, at the country level, the selection process is informed by the cost of medicines, which is reported in Table 2 for essential psychotropic medicines. The table presents the buyer price, that is the price available to organizations conducting the tender or procurement (typically countries), and the supplier price, that is the price available to organizations who maintain a warehouse and supply items directly to customers (i.e., international organizations doing fieldwork). For both indicators, we note that, for most second-generation antipsychotics and several selective serotonin reuptake inhibitors, the price was not available, which may indicate a price and affordability barrier. Likely, the fact that these medicines are now featured in the WHO EML will activate a process for their inclusion among those available for purchase internationally, with buyer and supply prices available. This inclusion may boost their purchase, which, in turn, should eventually bring down prices and increase the likelihood that they will be included in universal healthcare packages. Moreover, public health organizations such as the United Nations’ Medicines Patent Pool might negotiate licensing agreements with pharmaceutical companies to manufacture competitive generics of some of the included medicines (Burrone et al., Reference Burrone, Gotham, Gray, de Joncheere, Magrini, Martei, Gore and Kieny2019).

Taking into consideration, the availability potential of psychotropic medicines during the selection process may be relevant given existing evidence showing that, while alignment of the WHO EML with national formularies is substantial for psychotropic medicines (Todesco et al., Reference Todesco, Ostuzzi, Gastaldon, Papola and Barbui2023), the availability of the selected medicines is rather poor at the country level, especially in LMICs (Shi et al., Reference Shi, Zhang, Fu, Shao and Yan2023; Todesco et al., Reference Todesco, Ostuzzi and Barbui2022). Decision-makers could, therefore, consider the potential availability of psychotropic medicines as a factor informing the selection process, aiming to select from the WHO EML the medicines that are more likely to be widely available in relation to the characteristics of each country's healthcare system organization and development.

In conclusion, the updated WHO EML provides an exceptional chance to enhance the selection of the safest and most effective psychotropic medicines at the country level. It may also facilitate the implementation of regulatory policies that enhance their accessibility. These endeavours can significantly promote global mental health equity and expand universal health coverage. Ultimately, this should lead to the creation of a more inclusive and equitable mental healthcare system worldwide.